Bosch and Randox Invest Heavily in the Vivalytic Platform

Bosch and Randox Invest Heavily in the Vivalytic Platform

With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories, a diagnostic and medical technology company.

The two companies will invest around €150 million in joint research, development, and sales activities for new tests for the Vivalytic analysis platform provided by Bosch Healthcare. One goal is the development of a sepsis IVD grade test that will be the first to feature highly innovative and novel BioMEMS technology. Bosch has defined medical technology as a strategic growth field. Point-of-care molecular diagnostics is expected to become a future market worth billions. And with its Vivalytic analysis platform, Bosch aims to achieve a leading position in this market.

“With cutting-edge technology from our own labs and our own production lines, we want to grow long-term together with partners in the field of precision diagnostics,” said Stefan Hartung, chairman of the Bosch board of management. “Here, our medical technology can draw considerable benefit from our diversification, from our expertise, from the groundwork we have done in automation, miniaturization, molecular diagnostics, and from our experience in microchip development and manufacturing. We are investing long-term in an exciting high-tech growth field and continuously developing it together with partners. With technology ‘Invented for life’, we can relieve the burden on medical professionals and help make the diagnosis and treatment of disease faster.”

Bosch Healthcare Solutions and Randox are now joining forces in an attempt to accelerate the development and market launch of new tests and to make distribution channels more efficient. The partnership is set to run for more than ten years. With Vivalytic, the two companies aim to achieve sales in the medium nine-figure range by 2030. “Globally, healthcare is moving toward decentralized and personalized diagnostics, that enable rapid interventions and individual treatment plans,” says Marc Meier, managing director of Bosch Healthcare Solutions. “With our partner Randox, we want to further expand the test portfolio of our Vivalytic analysis device. Our fully automated molecular-diagnostic PCR tests provide clarity directly at the site of sample collection, shorten waiting times, and take the strain off the healthcare system.”